Companies › Palatin Technologies
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PL8177 Melanocortin receptor agonist | MCIR | Phase 2 | Ulcerative Colitis | – |
| bremelanotide Melanocortin receptor 4 agonist | MC4R | Phase 2 | Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06565611 | bremelanotide | Phase 2 | Obesity | Metabolic and endocrine | Feb 2025 |
| NCT05466890 | PL8177 | Phase 2 | Ulcerative Colitis | Immunology | Feb 2025 |
Cash of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 7 months at that burn, to Jan 2027
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Oneness Biotech Rhythm Pharmaceuticals Biomea Fusion Enlivex Therapeutics Yarrow Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.